Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität Münster Corrensstraße 48 48149 Münster Germany.
Cells-in-Motion Cluster of Excellence (EXC 1003 - CiM) Westfälische Wilhelms-Universität Münster 48149 Münster Germany.
ChemistryOpen. 2020 Aug 27;9(8):874-889. doi: 10.1002/open.202000188. eCollection 2020 Aug.
The activity of pharmacologically active compounds can be increased by presenting a drug in a defined conformation, which fits exactly into the binding pocket of its target. Herein, the piperazine scaffold was conformationally restricted by substituted C- or C-bridges across the 2- and 6-position. At first, a three-step, one-pot procedure was developed to obtain reproducibly piperazine-2,6-diones with various substituents at the N-atoms in high yields. Three strategies for bridging of piperazine-2,6-diones were pursued: 1. The bicyclic mixed ketals 8-benzyl-6-ethoxy-3-(4-methoxybenzyl)-6-(trimethylsilyloxy)-3,8-diazabicyclo[3.2.1]octane-2,4-diones were prepared by Dieckmann analogous cyclization of 2-(3,5-dioxopiperazin-2-yl)acetates. 2. Stepwise allylation, hydroboration and oxidation of piperazine-2,6-diones led to 3-(3,5-dioxopiperazin-2-yl)propionaldehydes. Whereas reaction of such an aldehyde with base provided the bicyclic alcohol 9-benzyl-6-hydroxy-3-(4-methoxybenzyl)-3,9-diazabicyclo[3.3.1]nonane-2,4-dione in only 10 % yield, the corresponding sulfinylimines reacted with base to give -(2,4-dioxo-3,9-diazabicyclo[3.3.1]nonan-6-yl)-2-methylpropane-2-sulfinamides in >66 % yield. 3. Transformation of a piperazine-2,6-dione with 1,4-dibromobut-2-ene and 3-halo-2-halomethylprop-1-enes provided 3,8-diazabicyclo[3.2.1]octane-2,4-dione and 3,9-diazabicyclo[3.3.1]nonane-2,4-dione with a vinyl group at the C- or a methylene group at the C-bridge, respectively. Since bridging via sulfinylimines and the one-pot bridging with 3-bromo-2-bromomethylprop-1-ene gave promising yields, these strategies will be exploited for the synthesis of novel receptor ligands bearing various substituents in a defined orientation at the carbon bridge.
药物以特定构象呈现时其药理活性会增强,因为该构象与靶标蛋白的结合口袋精确匹配。在此,通过在 2-位和 6-位引入取代的 C-或 C-桥,将哌嗪骨架刚性固定。首先,开发了一种三步一锅法,以高收率重现性地获得各种取代的哌嗪-2,6-二酮。尝试了三种桥连哌嗪-2,6-二酮的策略:1. 通过 Dieckmann 类似环化 2-(3,5-二氧代哌嗪-2-基)乙酸酯,制备了二环混合缩酮 8-苄基-6-乙氧基-3-(4-甲氧基苄基)-6-(三甲基甲硅烷基氧基)-3,8-二氮杂双环[3.2.1]辛烷-2,4-二酮。2. 哌嗪-2,6-二酮的逐步烯丙基化、硼氢化和氧化导致得到 3-(3,5-二氧代哌嗪-2-基)丙醛。而这种醛与碱反应仅得到收率为 10%的二环醇 9-苄基-6-羟基-3-(4-甲氧基苄基)-3,9-二氮杂双环[3.3.1]壬烷-2,4-二酮,而相应的亚磺酰亚胺基与碱反应则以大于 66%的收率得到-(2,4-二氧代-3,9-二氮杂双环[3.3.1]壬烷-6-基)-2-甲基丙烷-2-磺酰胺基。3. 用 1,4-二溴-2-丁烯和 3-卤-2-卤甲基丙烯-1-烯转化哌嗪-2,6-二酮,分别得到在 C-位带有乙烯基基团或在 C-桥位带有亚甲基基团的 3,8-二氮杂双环[3.2.1]辛烷-2,4-二酮和 3,9-二氮杂双环[3.3.1]壬烷-2,4-二酮。由于亚磺酰亚胺基桥连和与 3-溴-2-溴甲基丙烯-1-烯一锅法桥连均获得了有前景的产率,因此这些策略将用于合成带有各种取代基的新型受体配体,取代基在碳桥上以特定的方向排列。